Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.

This study found that ketorolac tert-butyl ester enhances skin permeation and follicular absorption compared to ketorolac, highlighting the role of lipophilicity and solubility in prodrug design.

In this case study, an 8-year-old boy with alopecia totalis experienced significant hair regrowth after baricitinib treatment, suggesting KRT74 variants may influence immune dysregulation in this condition.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

Tofacitinib might be used to treat hair loss.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

In this study, follicular unit extraction grafting using a patient's own scalp follicles showed promise in healing chronic ulcers in a woman with recessive dystrophic epidermolysis bullosa.

This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

This report details a case of dystrophic epidermolysis bullosa in a 37-year-old male with a recessive mutation in the CLO7A1 gene, affecting type VII collagen.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.